Evommune (EVMN) Current Assets (2024 - 2026)

Evommune (EVMN) has 3 years of Current Assets data on file, last reported at $215.9 million in Q1 2026.

• Current Assets for Q1 2026 came in at $215.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $215.9 million (changed N/A YoY), and the FY2025 annual result was $153.5 million, up 107.44% from the prior year.
• Current Assets rose to $215.9 million in Q1 2026 per EVMN's latest filing, from $153.5 million in the prior quarter.
• Over five years, Current Assets peaked at $215.9 million in Q1 2026 and troughed at $74.0 million in Q4 2024.
• A 3-year average of $131.3 million and a median of $117.7 million in 2025 frame the typical range for Current Assets.
• On a YoY basis, Current Assets climbed as much as 107.44% in 2025 and fell as far as 107.44% in 2025.
• A 3-year view of Current Assets shows it stood at $74.0 million in 2024, then surged by 107.44% to $153.5 million in 2025, then soared by 40.64% to $215.9 million in 2026.
• Business Quant data shows EVMN's Current Assets at $215.9 million in Q1 2026, $153.5 million in Q4 2025, and $81.9 million in Q3 2025.